Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the presently disclosed subject matter relates to methods and compositions for reducing or preventing actin cytoskeletal rearrangement and intercellular gap formation.
• the methods can be used to prevent actin cytoskeletal rearrangement that occurs in response to an ischemic event or an ischemia-reperfusion injury.
• AGP aminoalkyl glucosaminide phosphate
• ATP adenosine triphosphate
• IRI ischemia-reperfusion injury
• O 2 oxygen
• PBS phosphate buffered saline
• SIRS Systemic Inflammatory Response
• Acute lung injury is a feature of sepsis, systemic inflammatory response, and adult respiratory distress syndrome.
• Non-cardiogenic pulmonary edema and impaired gas exchange are consequences of acute lung injury, irrespective of etiology.
• the mechanisms causing pulmonary edema due to acute lung injury are not well understood.
• Ischemia-reperfusion injury (IR!) a form of acute lung injury occurring immediately following lung transplantation, is a frequent complication causing morbidity and mortality. See King et al., Ann. Thorac. Surg., 69, 1681-1685 (2000).
• Reperfusion following an interval of ischemia results in an inflammatory response involving components of the innate immune system, including the complement and coagulation cascades.
• lung IRI is likely relevant to many types of acute lung injury, and can be of benefit to substantial numbers of patients, in addition to lung transplant recipients. Such knowledge can also potentially be used to facilitate the retrieval of lungs from non-heart-beating cadaver donors for transplant, and/or assist in the salvage of sub-transplant quality lungs, See
• the presently disclosed subject matter provides a method of preventing or reducing actin cytoskeletal rearrangement in a cell, the method comprising contacting the cell with an effective amount of a compound of Formula (I):
• n is an integer from 1 to 6;
• Xi is O or S
• X 2 is O or S
• Ri , R 2 , and R 3 are independently C 2 -C 16 acyl, wherein at least one of Ri , R 2 , and R 3 is C 2 -C 7 acyl;
• n is 1.
• Xi and X 2 are each O.
• Ri, R 2 , and R 3 are each C 2 -C 7 acyl.
• the cell is a mammalian cell. In some embodiments, the cell is an endothelial cell. In some embodiments, preventing or reducing actin cytoskeletal rearrangement prevents or reduces intercellular gap formation between the cell and one or more cells surrounding the cell.
• contacting the cell occurs prior to an ischemic or ischemia-reperfusion-related event, during ischemia, or after an interval of ischemia, and preventing or reducing actin cytoskeletal rearrangement comprises preventing or reducing actin cytoskeletal rearrangement related to an ischemic or ischemia-reperfusion-related event.
• the presently disclosed subject matter provides a method of preventing or reducing actin cytoskeletal rearrangement in one or more cells in a subject, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
• preventing or reducing actin cytoskeletal rearrangement in one or more cells in the subject prevents or alleviates a disease or condition associated with increased actin cytoskeletal rearrangement, or a symptom thereof, in the subject.
• the subject is a mammal.
• FIG. 1A is a series of photographs of phallodian stained human pulmonary microvascular endothelial cells (HMVECs) showing the effect of simulated warm ischemia without hypoxia on actin cytockeletal rearrangement and on the formation of gaps in the human pulmonary microvascular endothelial monolayer.
• HMVECs human pulmonary microvascular endothelial cells
• the HMVECs were grown to confluence on P30 dishes with integral cover slips and incubated with either 1 ⁇ g/mL CRX-526 or vehicle prior to 1 hour of simulated warm ischemia (Wl).
• the photographs show CRX- 526-treated and vehicle-treated cells prior to Wl (Control), after 15 or 60 min Wl, and after 15, 60, or 240 min of simulated reperfusion (rep). Experiments were performed in triplicate.
• Figure 1 B is a graph of the % area of gaps in the monolayer of the cells shown in Figure 1 A.
• Three separate fields from each of three P30 dishes were analyzed (n 9 photos/time point).
• Vehicle treated cell data is shown in the shaded bars.
• CRX-526-treated cell data is shown in the open bars.
• Figure 1C is a graph of the % of abnormal actin in the cells shown in Figure 1A.
• HMVECs human pulmonary microvascular endothelial cells
• FIG. 2A is a series of photographs of (from left to right) human pulmonary microvascular endothelial cells (HMVECs) in warm (37°C) cell culture media (Control), of HMVECs after four hours of cold ischemia (Cl) in 4°C cell culture media (Media 4 hr Cl), of HMVECs after four hours of cold ischemia in 4°C PERFADEXTM (Vitrolife, Kungsbacka, Sweden) pulmonary preservation solution (Vehicle 4 hr Cl), and of HMVECs that had been pre- incubated with CRX-526 and undergone four hours of cold ischemia in 4°C PERFADEXTM (Vitrolife, Kungsbacka, Sweden) with CRX-526 (CRX-526 4 hr Cl).
• the photographs are representative of 9 images taken for each set of conditions.
• FIG. 2B is a graph of the % area of gaps in the monolayer of human pulmonary microvascular endothelial cells (HMVECs) in cell culture media (Media), vehicle (i.e., PERFADEXTM (Vitrolife, Kungsbacka, Sweden)) or in vehicle after a 1 hour pre-treatment with CRX-526 and following either four hours of cold ischemia (4hr Cl), 1 hour of warm ischemia (Wl), or following 1 hour of warm ischemia and 15 min, 1 hr, or 4 hr of reperfusion (15 min rep, 1 hr rep, and 4 hr rep, respectively). Data for the HMVECs in cell culture media without vehicle is shown in the open bars.
• HMVECs human pulmonary microvascular endothelial cells
• alkyl refers to Ci -2O inclusive, linear (i.e., "straight-chain"), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, fe/t-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyi, and allenyl groups.
• Branched refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain.
• Lower alkyl refers to an alkyl group having 1 to about 6 carbon atoms (i.e., a Ci -7 alkyl), e.g., 1 , 2, 3, 4, 5, or 6 carbon atoms.
• Higher alkyl refers to an alkyl group having about 8 to about
• 20 carbon atoms e.g., 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms.
• Alkyl groups can optionally be substituted (a "substituted alkyl") with one or more alkyl group substituents, which can be the same or different.
• alkyl group substituent includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.
• alkyl chain There can be optionally inserted along the alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl”), or aryl.
• substituted alkyl includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group are replaced with another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.
• alkenyl refers to an alkyl group comprising one or more carbon-carbon double bonds.
• aryl is used herein to refer to an aromatic substituent that can be a single aromatic ring, or multiple aromatic rings that are fused together, linked covalently, or linked to a common group, such as, but not limited to, a methylene or ethylene moiety.
• the common linking group also can be a carbonyl, as in benzophenone, or oxygen, as in diphenylether, or nitrogen, as in diphenylamine.
• aryl specifically encompasses heterocyclic aromatic compounds.
• the aromatic ring(s) can comprise phenyl, naphthyl, biphenyl, diphenylether, diphenylamine and benzophenone, among others.
• aryl means a cyclic aromatic comprising about 5 to about 10 carbon atoms, e.g., 5, 6, 7, 8, 9, or 10 carbon atoms, and including 5- and 6-membered hydrocarbon and heterocyclic aromatic rings.
• the aryl group can be optionally substituted (a "substituted aryl") with one or more aryl group substituents, which can be the same or different, wherein "aryl group substituent" includes alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, and -NR 1 R", wherein R 1 and R" can each be independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, and aralkyl.
• substituted aryl includes aryl groups, as defined herein, in which one or more atoms or functional groups of the aryl group are replaced with another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.
• aryl groups include, but are not limited to, cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole, and the like.
• Alkylene refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms.
• the alkylene group can be straight, branched or cyclic.
• the alkylene group also can be optionally unsaturated and/or substituted with one or more "alkyl group substituents.” There can be optionally inserted along the alkylene group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms (also referred to herein as "alkylaminoalkyl”), wherein the nitrogen substituent is alkyl as previously described.
• R is hydrogen or lower alkyl; methylenedioxyl (-0-CH 2 -O-); and ethylenedioxyl (-O-(CH 2 ) 2 -O-).
• An alkylene group can have about 2 to about 3 carbon atoms and can further have 6-20 carbons.
• hydroxy and hydroxyl refer to the group -OH.
• hydroxyalkyl refers to a hydroxy-terminated alkyl group. In some embodiments, the hydroxyalkyl group has the structure -(CH 2 ) n OH.
• carboxylate refers to anion formed when the H of the carboxylic acid group is removed.
• Carboxyiates can form salts (i.e., carboxylate salts) with cationic groups.
• phosphate also includes anionic species formed by the removal of one or more hydrogen atoms of the phosphate group.
• thiol refers to a group having the structure -S-R, wherein R is alkyl, acyl, or aryl.
• thiol can also refer to a compound having the structure H-S-R, wherein R is alkyl, acyl, or aryl.
• amino refers to a group having the structure -NRiR 2 , wherein Ri and R 2 are independently selected from the group H, alkyl, acyl, and aryl.
• the monomer units can include trioses, tetroses, pentoses, hexoses, heptoses, nonoses, and mixtures thereof.
• the monosaccharide can be in a cyclized form of the chemical structure.
• the compound will comprise a hemiacetal or hemiketal. !n some embodiments, the term “monosaccharide” refers to a cyclized monomer unit based on a compound having a chemica! structure
• monosaccharides include, but are not limited to, aldohexoses, aldopentoses, ketohexoses, and ketopentoses such as arabinose, lyxose, ribose, xylose, ribulose, xylulose, allose, altrose, galactose, glucose, gulose, idose, mannose, talose, fructose, psicose, sorbose, and tagatose.
• the term "monosaccharide analog” refers to a monosaccharide wherein one or more hydroxy! group of the monosaccharide is replaced by another chemical group, such as, but not limited to a phosphate, an amine, a thiol, or an alkyl group.
• amino sugar refers to a monosaccharide analog wherein one or more hydroxy! group of a monosaccharide is replaced by an amine.
• An exemplary amino sugar is glucosamine (i.e., 2-deoxy-2-amino- ⁇ -D- glucopyranose).
• fragment refers to a compound whose structure is any portion of the structure of the originally named compound that is less than the whole of the originally named compound. Thus, a fragment is smaller than the original compound, but generally retains some or all of the biological activity of the original compound.
• “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
• the presently disclosed compounds, materials, compositions, and/or dosage forms are pharmaceutically acceptable for use in humans.
• reducing refers to methods of treating a pre- existing condition or disease by, for example, reducing or alleviating the symptoms or effects of the condition or disease, to any degree.
• Preventing refers to methods of keeping a potential future condition, disease, disorder, or injury, or the symptoms thereof, from occurring, to any degree. “Preventing” can refer to methods of decreasing the effects of a future condition or injury, such that the effects of the future condition or injury are of lesser magnitude or shorter duration than the effects that would have occurred in the absence of the preventative action, as well as to methods of completely keeping the effects from occurring. Thus, “preventing” refers to prophylactic methods of medical and veterinary treatment. “Ischemia” refers to inadequate blood flow to a biological tissue or organ, which results in the organ or tissue's inability to meet demands for metabolism.
• Reperfusion resume of blood flow
• ROS reactive oxygen species
• RNS reactive nitrogen species
• Reperfusion resume of blood flow
• ROS reactive oxygen species
• RNS reactive nitrogen species
• oxidative stress which results in a series of events such as alterations in mitochondrial oxidative phosphorylation, depletion of ATP (which also occurs during and as a result of ischemia), an increase in intracellular calcium and activation of protein kinases, phosphatases, proteases, lipases and nucleases leading to loss of cellular function/integrity.
• Ischemia reperfusion injury refers to an injury which occurs after blood circulation is restarted in an organic tissue subjected to ischemia (e.g., when an organ is excised by operation and re-attached, as in a transplant or auto-transplant).
• IRI Ischemia reperfusion injury
• ischemia e.g., when an organ is excised by operation and re-attached, as in a transplant or auto-transplant.
• PTCA percutaneous transluminal coronary angioplasty
• stent or bypass after myocardial infarction
• administration of a thrombolytic to a stroke patient is another example.
• Another example is when blood flow to the heart is temporarily stopped for cardiac surgery, often by the prior administration of cardioplegia solutions.
• IRI can include, but is not limited to, cerebral, retinal, hepatic, renal, pancreatic, spinal cord, mesenteric, limb, intestinal, brain, myocardial, central nervous system, skin, or lung ischemia reperfusion injury, or a combination thereof.
• ischemia-reperfusion injury is a serious problem in organ transplantation because the harvested organ is removed from the body of a donor, isolated from a blood source, and thus deprived of nutrients and often oxygen for an extended period of time, typically.
• Edema refers to an increase in interstitial fluid in a tissue or organ. In the lung, “edema” can also refer to an increase in alveolar fluid. In some embodiments, edema is associated with a condition involving increased endothelial cell permeability.
• Increased endothelial permeability refers to increased permeability of blood vessels in an organ or tissue to fluid and/or protein in the blood, resulting in edema, which can occur in a number of clinical scenarios, such as, but not limited to, Adult Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS) and in the setting of infection with a variety of bacteria.
• ARDS Adult Respiratory Distress Syndrome
• SIRS Systemic Inflammatory Response Syndrome
• the endothelial cytoskeleton plays a role in regulation of pulmonary vascular permeability. See Dudek and Garcia, J. Appl. Physiol., 91(4), 1487-1500 (2001). It has also been postulated that the cytoskeleton can function as an intracellular communication system or signaling scaffold. See Inqber, Faseb J., 20(7), 811-827, (2006).
• the presently disclosed subject matter relates to the observation that an aminoalkyl glucosaminide phosphate, CRX-526, reduces cytoskeletal rearrangement following simulated ischemia.
• the presently disclosed subject matter relates to the use of lipid A mimetic compounds that comprise monosaccharides or monosaccharide analogs.
• the monosaccharide analog is an amino sugar.
• the amino sugar is glucosamine.
• the presently disclosed subject matter relates to the use of aminoalkyl glucosaminide phosphates (AGPs) or pharmaceutically acceptable salts thereof.
• AGPs are synthetic (i.e., chemically synthesized) lipid A mimetics and can have a structure of Formula (I):
• n is an integer from 1 to 6;
• Xi is O or S
• X 2 is O or S
• R- I , R2, and R3 are independently C2-C16 acyl;
• R 5 , R 6 , and R 7 are independently Ci 0 -Ci 2 alkyl, or a pharmaceutically acceptable salt thereof.
• the AGP for use in the presently disclosed subject matter include at least one secondary acyl chain (i.e., Ri, R 2 , or R 3 ) that is less than eight carbons.
• at least two of Ri, R 2 , and R 3 are C 2 -C 7 acyl.
• R 5 , R 6 , and R 7 are each Ci 0 -Ci 2 straight-chain, fully saturated alkyi.
• the compounds of Formula (I) have asymmetric carbon atoms and can therefore exist as enantiomers or diastereomers.
• Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known per se, for example, by chromatography and/or fractional crystallization.
• Enantiomers can be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomers, enantiomers and mixtures thereof are considered as part of the presently disclosed subject matter.
• pharmaceutically acceptable salt as used herein in relation to compounds of the presently disclosed subject matter (e.g., the compounds of Formula (I)) includes pharmaceutically acceptable cationic salts.
• pharmaceutically-acceptable cationic salts is intended to define but is not limited to such salts as the alkali metal salts, (e.g., sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N'-dibenzylethylenediamine), choline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, meglumine (N- methylglucamine), benethamine (N-benzylphenethylamine), ethanolamine, diethylamine, piperazine, triethanolamine (2-amino-2-hydroxymethyl-1 ,3- propanediol) and procaine.
• compositions of the compounds of Formula (I) can be readily prepared by reacting the free acid form of said compounds with an appropriate base, usually one or more equivalent, in a co-solvent.
• Co-solvents can include, but are not limited to, diethylether, diglyme and acetone.
• Bases can include, but are not limited to, sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, ethanolamine, diethanolamine, piperazine and triethanolamine.
• the salt is isolated by concentration to dryness or by addition of a non-solvent.
• salts can be prepared by mixing a solution of the acid with a solution of a different salt of the cation (e.g., sodium or potassium ethylhexanoate, magnesium oleate) and employing a co-solvent, as described above, from which the desired cationic salt precipitates, or can be otherwise isolated by concentration.
• a different salt of the cation e.g., sodium or potassium ethylhexanoate, magnesium oleate
• the presently disclosed subject matter relates to methods of preventing or reducing actin cytoskeletal rearrangement.
• the presently disclosed subject matter provides a method of preventing or reducing actin cytoskeletal rearrangement in a cell, the method comprising contacting the cell with an effective amount of a compound of Formula (I):
• n is an integer from 1 to 6;
• X 1 is O or S
• X 2 is O or S; Ri, R 2 , and R 3 are independently C 2 -Ci 6 acyl;
• R 5 , R 6 , and R 7 are independently Ci 0 -Ci 2 alkyl, or a pharmaceutically acceptable salt thereof.
• R 5 , R 6 , and R 7 are each Ci 0 -Ci 2 straight-chain, fully saturated alkyl.
• n is 1.
• Xi and X 2 are each O.
• Ri, R 2 , and R 3 are each C 2 -C 7 acyl.
• the cell of the presently disclosed methods can be any suitable cell.
• Suitable cells include, but are not limited to, osteoblasts, osteoclasts, chondrocytes, adipocytes, fibroblasts, endothelial cells, epithelial cells, mesenchymal cells, hematopoietic cells, sensory cells, endocrine and exocrine glandular cells, glia cells, neuronal cells, oligodendrocytes, blood cells, intestinal cells, brain cells, cardiac cells, lung cells, liver cells, kidney cells, muscle cells, and pancreatic cells.
• the cell is a eukaryotic cell.
• the eel! is a mammalian cell.
• the cell is a human cell.
• the cell is an endothelial cell.
• the presently disclosed subject matter relates to regulation of endothelial cell permeability.
• the presently disclosed subject matter provides a method of regulating endothelial cell permeability, wherein the method comprises contacting an endothelial cell with a compound of Formula (S).
• Regulation of cell permeability can result in the maintenance of normal levels of interstitial fluid (and/or alveolar fluid) surrounding the contacted cell or in a decrease in interstitial fluid (and/or alveolar fluid).
• regulation of cell permeability prevents an increase in interstitial fluid or alveolar fluid that would otherwise have resulted from a disease or event (such as infection or an ischemia-reperfusion injury).
• the method of preventing or reducing actin cytoskeletal rearrangement prevents or reduces intercellular gap formation between the cell and one or more additional cells surrounding the cell.
• the actin cytoskeletal rearrangement can be associated with edema, including pulmonary edema or edema in other organs.
• the edema can be associated with inflammation, infection, trauma (e.g., surgery), inhalation of a toxin, a circulatory disorder, or exposure to high altitudes.
• preventing or reducing actin cytoskeletal rearrangement comprises preventing or reducing actin cytoskeletal rearrangement that is associated with a condition characterized by increased endothelial permeability.
• the edema to be prevented or reduced is associated with ischemia-reperfusion, such as during organ transplantation, pulmonary embolectomy (removal of clotted blood from pulmonary arteries), or pulmonary thromboendarterectomy (surgical removal of organized clot and fibrin from the pulmonary vasculature).
• the cell is contacted with an effective amount of the compound of Formula (S) prior to a simulated or predicted ischemic or ischemia-reperfusion event (e.g., removal of tissue for organ transplant, tissue transplant, cardioplegia, application of a tourniquet, etc.) to prevent or reduce actin cytoskeletal rearrangement during the ischemia or subsequent reperfusion.
• the cell can be contacted with the compound of Formula (I) during ischemia.
• the cell can be contacted with the compound of Formula (I) after an interval of ischemia (e.g., during reperfusion).
• the ischemia-reperfusion event is related to myocardial infarction or stroke. In some embodiments, the ischemia- reperfusion event is related to cardioplegia (i.e., when cardiac activity is stopped intentionally) during cardiac surgery or to ischemia in skeletal muscle resulting from orthopedic surgery (e.g., when a tourniquet is applied to a limb to reduce blood in the surgical field).
• cardioplegia i.e., when cardiac activity is stopped intentionally
• ischemia in skeletal muscle resulting from orthopedic surgery e.g., when a tourniquet is applied to a limb to reduce blood in the surgical field.
• the presently disclosed subject matter relates to in vitro or ex vivo methods, wherein the cell is not located in a living organism.
• the cell can be present in a cell culture or in an ex vivo tissue or organ.
• in vitro or ex vivo methods can be used to determine the relative ability of compounds to prevent or reduce actin cytoskeletal rearrangement or to determine a dosage of a particular compound in a particular cell type.
• an ex vivo method can be used to treat a cell present in a tissue or organ intended for transplant.
• the cell is present in a living organism.
• the presently disclosed subject matter provides a method of preventing or reducing actin cytoskeletal rearrangement in one or more cells in a subject, the method comprising administering to the subject an effective amount of a compound of Formula (I):
• n is an integer from 1 to 6;
• X 2 is O or S
• R-I, R 2 , and R 3 are independently C2-C1 6 acyl
• R 5 , Re, and R 7 are independently Ci 0 -Ci 2 a!kyl, or a pharmaceutically acceptable salt thereof.
• R 5 , RQ, and R 7 are each C1 0 -C1 2 straight-chain, fully saturated alkyl.
• n is 1.
• Xi and X 2 are each O.
• Ri, R 2 , and R 3 are each C 2 -C 7 acyl.
• preventing or reducing actin cytoskeletal rearrangement in one or more cells in the subject prevents or alleviates a disease or condition associated with increased actin cytoskeletal rearrangement, or a symptom thereof, in the subject.
• the disease or condition can be any disease or condition characterized by edema.
• the edema is associated with increased epithelial cell permeability.
• the disease or condition is ARDS or SIRS.
• the disease or condition is associated with IRI.
• the disease or condition can be related to IRI associated with organ or tissue transplantation (including xeno-transplantation or auto- transplantation), cardioplegia, myocardial infarction, stroke, elective orthopedic surgery, liver surgeries involving the Pringle maneuver, or other surgeries wherein blood flow is restricted to a tissue.
• the condition can be related to IRI associated with lung transplant.
• the administration of the compound of Formula (I) can be via any suitable route (i.e., oral, intravenous, parenteral, via the airway, etc.).
• the contacting can take place prior to an ischemic event, during ischemia, or following an interval is ischemia (e.g., during reperfusion).
• the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the eel! or cells are present in an organ or tissue selected from the group including, but not limited to, a kidney or a portion thereof, a liver or a portion thereof, a heart or a portion thereof, a retina, a pancreas or a portion thereof, a bowel or a portion thereof, brain tissue, skeletal muscle, or a lung or a portion thereof.
• the term “active compound” refers to any compound that can inhibit cytoskeletal rearrangement and/or intercellular gap formation.
• the term refers to compounds of Formula (I) and their salts.
• the active compound can be contacted to the cell or administered to the subject through any suitable approach.
• the term “effective amount” refers to an amount of active compound or active compounds which is capable of inhibiting or preventing various pathological conditions and sequelae, herein described.
• inhibitor refers to prohibiting, preventing, treating, alleviating, ameliorating, halting, restraining, reducing, slowing or reversing the progression, or reducing the severity of a pathological condition, such as, but not limited to, a condition related to or resultant from tissue damage (e.g., lung tissue damage) in subjects who are at risk for diseases or conditions related to increased cytoskeletal rearrangement.
• a pathological condition such as, but not limited to, a condition related to or resultant from tissue damage (e.g., lung tissue damage) in subjects who are at risk for diseases or conditions related to increased cytoskeletal rearrangement.
• tissue damage e.g., lung tissue damage
• the presently disclosed methods of administering active compounds include both medical therapeutic (acute) and/or prophylactic (prevention) administration, as appropriate.
• the amount and timing of active compound administered can, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician.
• the dosages given below are a guideline and the physician can titrate doses of the compound to achieve the treatment that the physician considers appropriate for the subject.
• the physician can balance a variety of factors such as age of the subject, presence of preexisting disease, as well as presence of other diseases.
• Pharmaceutical formulations can be prepared for oral, intravenous, or aerosol administration as discussed in greater detail below.
• the therapeutically effective dosage of any specific active compound can vary somewhat from compound to compound, and subject to subject, and can depend upon the condition of the subject and the route of delivery.
• a dosage from about 0.1 to about 50 mg/kg can have therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed.
• Toxicity concerns at the higher level can restrict intravenous dosages to a lower level, such as up to about 10 mg/kg, with all weights being calculated based on the weight of the active base, including the cases where a salt is employed.
• a dosage from about 10 mg/kg to about 50 mg/kg can be employed for oral administration.
• a dosage from about 0.5 mg/kg to 5 mg/kg can be employed for intramuscular injection.
• dosages can be from about 1 ⁇ mol/kg to about 50 ⁇ mol/kg, or, optionally, between about 22 ⁇ mol/kg and about 33 ⁇ mol/kg of the compound for intravenous or oral administration.
• in vitro and in vivo assays described herein provide an approach wherein the activities of compounds can be compared.
• the results of these comparisons are useful for determining dosage levels in mammals, including humans, for inducing protection from actin cytoskeletal rearrangement.
• Such assays provide for the comparison of activities of the compounds of Formula ⁇ and other compounds.
• the results of these comparisons are useful for determining such dosage levels.
• pharmaceutically active compounds as described herein can be administered orally as a solid or as a liquid, or can be administered intramuscularly, intravenously or via the airway (e.g., by inhalation) as a solution, suspension, or emulsion.
• the compounds or salts also can be administered by inhalation, intravenously, or intramuscularly as a liposomal suspension.
• the active compound or salt can be in the form of a plurality of solid particles or droplets having a particle size from about 0.5 to about 5 microns, and optionally from about 1 to about 2 microns.
• the pharmaceutical formulations can comprise an active compound described herein or a pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable carrier.
• water is the carrier of choice with respect to water-soluble compounds or salts.
• an organic vehicle such as glycerol, propylene glycol, polyethylene glycol, or mixtures thereof, can be suitable. Sn the latter instance, the organic vehicle can contain a substantial amount of water.
• the solution in either instance can then be sterilized in a suitable manner known to those in the art, and typically by filtration through a 0.22- micron filter. Subsequent to sterilization, the solution can be dispensed into appropriate receptacles, such as depyrogenated glass vials. The dispensing is optionally done by an aseptic method. Sterilized closures can then be placed on the vials and, if desired, the vial contents can be lyophilized.
• the pharmaceutical formulations can contain other additives, such as pH-adjusting additives.
• useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
• the formulations can contain antimicrobial preservatives.
• Useful antimicrobial preservatives include methylparaben, propylparaben, and benzyl alcohol. The antimicrobial preservative is typically employed when the formulation is placed in a vial designed for multi-dose use.
• the pharmaceutical formulations described herein can be lyophilized using techniques well known in the art.
• a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like.
• Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch (e.g., potato or tapioca starch) and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
• binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
• lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
• Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules.
• compositions in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
• lactose or milk sugar as well as high molecular weight polyethylene glycols.
• the compounds of the presently disclosed subject matter can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
• an injectable, stable, sterile formulation comprising an active compound as described herein, or a salt thereof, in a unit dosage form in a sealed container.
• the compound or salt is provided in the form of a lyophilizate, which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid formulation suitable for injection thereof into a subject.
• a sufficient amount of emulsifying agent which is physiologically acceptable, can be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
• Particularly useful emulsifying agents include phosphatidyl cholines and lecithin.
• Additional embodiments provided herein include liposomal formulations of the active compounds disclosed herein.
• the technology for forming liposomal suspensions is well known in the art.
• the compound is an aqueous-soluble salt, using conventional liposome technology, the same can be incorporated into lipid vesicles.
• the active compound due to the water solubility of the active compound, the active compound can be substantially entrained within the hydrophilic center or core of the liposomes.
• the lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free.
• the active compound of interest is water-insoluble, again employing conventional liposome formation technology, the salt can be substantially entrained within the hydrophobic lipid bilayer that forms the structure of the liposome.
• the liposomes that are produced can be reduced in size, as through the use of standard sonication and homogenization techniques.
• the liposomal formulations comprising the active compounds disclosed herein can be lyophilized to produce a lyophilizate, which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.
• compositions which are suitable for administration as an aerosol by inhalation. These formulations comprise a solution or suspension of a desired compound described herein or a salt thereof, or a plurality of solid particles of the compound or sait.
• the desired formulation can be placed in a small chamber and nebulized. Nebulization can be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising the compounds or salts.
• the liquid droplets or solid particles should have a particle size in the range of about 0.5 to about 10 microns, and optionally from about 0.5 to about 5 microns.
• the solid particles can be obtained by processing the solid compound or a salt thereof, in any appropriate manner known in the art, such as by micronization.
• the size of the solid particles or droplets can be from about 1 to about 2 microns.
• commercial nebulizers are available to achieve this purpose.
• the compounds can be administered via an aerosol suspension of respirable particles in a manner set forth in U.S. Patent No. 5,628,984, the disclosure of which is incorporated herein by reference in its entirety.
• the pharmaceutical formulation suitable for administration as an aerosol is in the form of a liquid
• the formulation can comprise a water-soluble active compound in a carrier that comprises water.
• a surfactant can be present, which lowers the surface tension of the formulation sufficiently to result in the formation of droplets within the desired size range when subjected to nebulization.
• water-soluble and water-insoluble active compounds are provided.
• water-soluble is meant to define any composition that is soluble in water in an amount of about 50 mg/mL, or greater.
• water-insoluble is meant to define any composition that has a solubility in water of less than about 20 mg/mL.
• water-soluble compounds or salts can be desirable whereas in other embodiments water-insoluble compounds or salts likewise can be desirable.
• the compounds of the presently disclosed subject matter can be administered just prior to a surgery (e.g., within twenty- four hours before surgery, for example, cardiac surgery or transplant surgery), during and/or subsequent to surgery (e.g., within twenty-four hours after surgery) where there is risk of ischemia.
• the active compounds are administered with an initial loading dose (e.g., bolus injection or infusion) prior to surgery followed by a constant infusion prior to, during and post surgery.
• the active compounds can also be administered in a chronic daily mode.
• compositions according to the presently disclosed subject matter can contain, for example, 0.0001 %-95% of the active compound(s).
• the composition or formulation to be administered can contain a quantity of an active compound(s) in an amount effective to treat the disease/condition of the subject being treated.
• the methods of the presently disclosed subject matter can be used to prevent or reduce actin cytoskeletal rearrangement and/ or intercellular gap formation in extracorporeal tissue or organs or in tissue or organs that are being transplanted from a tissue or organ donor into a transplant recipient.
• Extracorporeal tissue or organs are tissue or organs not in an individual (also termed ex vivo).
• donor tissue and organs removed are also susceptible to reperfusion injury during harvesting, while in transit and following transplantation into a recipient.
• the presently disclosed methods can be used to increase the viability of a transplantable tissue or organ by, for example, supplementing solutions used to maintain or preserve transplantable tissues or organs.
• the methods and compositions can be used to bathe the transplantable tissue or organ during transport or can be placed in contact with the transplantable tissue or organ prior to, during or after transplantation.
• formulations of the presently disclosed subject matter can be contacted to a tissue or organ while the tissue or organ is present in the donor.
• a perfusion device as used herein is any mechanical device that be used to infuse a specific organ or the systemic circulation with a solution comprising a compound or composition.
• a device can contain one or more reservoirs.
• the device can include a tube, catheter, or cannula leading from the reservoir that can be inserted into an organ, vein or artery.
• the device can be an electromechanical device having electric pumps and devices for controlling the temperature, rate or volume of delivery of the solution.
• the device is programmable so that the one or more solutions are delivered in an appropriate temperature, rate or volume for a particular clinical situation, weight of the organ, or size of the organ (e.g., cardiopulmonary bypass surgery vs. kidney transplant vs. liver transplant).
• the subject treated in the presently disclosed subject matter is desirably a human subject, although it is to be understood the methods described herein are effective with respect to all vertebrate species, which are intended to be included in the term "subject.”
• the methods described herein are particularly useful in the treatment and/or prevention of actin cytoskeletal rearrangement in cells of warm-blooded vertebrates.
• the methods can be used as treatment for mammals and birds.
• the subject of the presently disclosed method is an organ transplant recipient.
• mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses.
• carnivores other than humans such as cats and dogs
• swine pigs, hogs, and wild boars
• ruminants such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels
• Also provided herein is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos or as pets, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they also are of economical importance to humans.
• embodiments of the methods described herein include the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.
• HMVECs Human pulmonary microvascular endothelial cells
• CLONETICS® EGM-2MV BULLETKITS® Bactet Cells
• Sealed PLEXSGLAS® containers housing culture dishes at 37 0 C were ventilated with 95% O 2 /5% CO 2 .
• Dishes were pre-treated with 1 ⁇ g/mL CRX-526 (GlaxoSmithKline, Duluth, Minnesota, United States of America) orvehicle (2% glycerin), one hour before Wl.
• CRX-526 or vehicle was added whenever medium was changed.
• HMVECs were fixed in 4% paraformaldehyde for 10 minutes at room temperature and washed 3 times with PBS. Cells were incubated for 1 hour with a 1/100 dilution of ALEXAFLOR® 568 phalloidin (Invitrogen, Carlsbad, California, United States of America) in PBS with 1 % BSA and 0.05% Tween- 20. Coverslips stained for F-actin were immediately examined with a Leica DMIRB Inverted Fluorescence/DIC microscope (Leica Microsystems, Inc., Bannockburn, Illinois, United States of America) at 2OX and 40X magnification to evaluate changes in cell shape and F-actin cytoskeleton.
• Culture medium and Ringer's lactate were used as background controls to normalize the absorbance value from the other samples.
• Cytotoxicity was calculated as media LDH activity divided by total LDH activity (cell pellet plus media). Viability was the inverse and expressed as percent viability at each time point.
• hypoxia does not appear to be a general feature of lung ischemia, particularly in lungs inflated with 100% oxygen. Therefore, the presently disclosed in vitro model is believed to accurately reflect in vivo events, although nutrient depletion and development of acidosis would be more gradual in vivo.
• HMVECs grown to confluence on P30 dishes with integral cover slips were incubated with 1 ⁇ g/mL CRX-526 or vehicle, ventilated with 95% O 2 /5% CO 2 . Media was replaced with warm (37°C)
• FIG. 2A shows the effect of replacement of warm cell culture media with cold PERFADEXTM (Vitrolife, Kungsbacka, Sweden), the most commonly employed lung preservation solution in the world, on HMVECs.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (2)

Family

ID=41162617

Family Applications (1)

Country Status (14)

Cited By (2)

Families Citing this family (3)

Family Cites Families (16)

• 2009
  • 2009-04-09 JP JP2011504178A patent/JP5562939B2/ja not_active Expired - Fee Related
  • 2009-04-09 EA EA201001450A patent/EA201001450A1/ru unknown
  • 2009-04-09 ES ES09730162.6T patent/ES2569608T3/es active Active
  • 2009-04-09 KR KR1020107024897A patent/KR20100135886A/ko not_active Withdrawn
  • 2009-04-09 AU AU2009234156A patent/AU2009234156A1/en not_active Abandoned
  • 2009-04-09 WO PCT/US2009/040098 patent/WO2009126822A2/en not_active Ceased
  • 2009-04-09 CN CN200980121482.3A patent/CN102083443B/zh not_active Expired - Fee Related
  • 2009-04-09 US US12/936,801 patent/US8809303B2/en not_active Expired - Fee Related
  • 2009-04-09 EP EP09730162.6A patent/EP2268286B1/en active Active
  • 2009-04-09 BR BRPI0911195A patent/BRPI0911195A2/pt not_active IP Right Cessation
  • 2009-04-09 CA CA2721082A patent/CA2721082A1/en not_active Abandoned
  • 2009-04-09 MX MX2010011050A patent/MX2010011050A/es active IP Right Grant
• 2010
  • 2010-10-07 IL IL208565A patent/IL208565A0/en unknown
  • 2010-10-28 ZA ZA2010/07735A patent/ZA201007735B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events